Literature DB >> 10760381

Increased QT variability in patients with panic disorder and depression.

V K Yeragani1, R Pohl, V C Jampala, R Balon, C Ramesh, K Srinivasan.   

Abstract

This study investigated beat-to-beat QT variability in patients with panic disorder and depression, and normal control subjects using an automated algorithm to compute QT intervals. An increase in QT variability appears to be associated with symptomatic patients with dilated cardiomyopathy and also with an increased risk for sudden death. QT(vm) (QT variability normalized for mean QT interval) and QT(vi) (a log ratio of QT variance normalized for mean QT over heart rate variability normalized for mean heart rate) were significantly higher in patients with panic disorder and depression in supine as well as standing postures (P=0.002 and 0.0001 for QT(vm) and QT(vi), respectively). In another analysis, QT(vi) was significantly higher in patients with panic disorder compared to control subjects in supine as well as standing postures during spontaneous breathing as well as 12, 15 and 20 per minute breathing (P=0.005). These findings are important especially in view of the recent reports of increased risk for cardiovascular mortality and sudden death in patients with anxiety and depression and the utility of QT(vi) as a noninvasive measure of temporal repolarization lability.

Entities:  

Mesh:

Year:  2000        PMID: 10760381     DOI: 10.1016/s0165-1781(00)00119-0

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  24 in total

1.  Effect of imipramine on linear and nonlinear measures of heart rate variability in children.

Authors:  K Srinivasan; M V Ashok; M Vaz; V K Yeragani
Journal:  Pediatr Cardiol       Date:  2003-11-07       Impact factor: 1.655

Review 2.  Non-invasive electrocardiographic assessments of cardiac autonomic modulation in individuals with spinal cord injury.

Authors:  H Sharif; P J Millar; A V Incognito; D S Ditor
Journal:  Spinal Cord       Date:  2015-11-24       Impact factor: 2.772

3.  A new potential marker for abnormal cardiac physiology in depression.

Authors:  Grant L Iverson; Michael B Gaetz; Edward J Rzempoluck; Peter McLean; Wolfgang Linden; Ronald Remick
Journal:  J Behav Med       Date:  2005-10-13

4.  Effect of age on diurnal changes of 24-hour QT interval variability.

Authors:  V K Yeragani; R Berger; R Pohl; R Balon
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

5.  Cardiac risk and schizophrenia.

Authors:  Ripu Jindal; Erin M MacKenzie; Glen B Baker; Vikram K Yeragani
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

6.  Effects of Escitalopram on Autonomic Function in Posttraumatic Stress Disorder Among Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF).

Authors:  Sriram Ramaswamy; Vithyalakshmi Selvaraj; David Driscoll; Jayakrishna S Madabushi; Subhash C Bhatia; Vikram Yeragani
Journal:  Innov Clin Neurosci       Date:  2015 May-Jun

Review 7.  Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?

Authors:  Josephine Elia; Victoria L Vetter
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 8.  Towards a better understanding of QT interval variability.

Authors:  Larisa G Tereshchenko; Ronald D Berger
Journal:  Ther Adv Drug Saf       Date:  2011-12

9.  Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis.

Authors:  Ripu D Jindal; Matcheri S Keshavan; Kevin Eklund; Angela Stevens; Debra M Montrose; Vikram K Yeragani
Journal:  Schizophr Res       Date:  2009-07-01       Impact factor: 4.939

10.  Mean and variability of QT-interval: Relevance to psychiatric illness and psychotropic medication.

Authors:  Rahul Kumar; Chaitra T Ramachandraiah; Pratap Chokka; Vikram K Yeragani
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.